Production (Stage)
Carisma Therapeutics, Inc.
CARM
$0.4081
-$0.0216-5.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 37.49% | 30.39% | 22.82% | 8.90% | -8.93% |
| Total Depreciation and Amortization | -39.29% | 18.22% | 20.82% | 18.07% | 60.71% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Other Non-Cash Items | -2.99% | 30.49% | 56.39% | 54.66% | 17.66% |
| Change in Net Operating Assets | 20.40% | -119.87% | -63.29% | -694.76% | -174.39% |
| Cash from Operations | 39.08% | 26.19% | 17.67% | -8.83% | -19.64% |
| Capital Expenditure | 89.55% | 89.13% | 23.15% | 70.94% | 73.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -85.65% | -12.29% | 141.50% |
| Cash from Investing | -99.45% | -100.17% | -86.39% | -8.26% | 170.45% |
| Total Debt Issued | -100.00% | -42.01% | -70.23% | -67.91% | -71.41% |
| Total Debt Repaid | 54.52% | -15.53% | -41.85% | -190.30% | -244.79% |
| Issuance of Common Stock | -95.57% | -92.30% | -89.88% | -90.19% | -90.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -102.51% | -112.51% |
| Cash from Financing | 61.19% | -99.45% | -98.24% | -100.81% | -106.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -675.19% | -211.77% | -203.80% | -198.19% | -121.77% |